Other medications

BI 690517 is an aldosterone synthase inhibitor. This class of drug can be recognised by the following letters at the end of the name “drostat”. Examples include baxdrostat and lorundrostat.

Empagliflozin is a sodium-glucose co-transporter-2 inhibitor. This class of drug can be recognised by the following letters at the end of the name “flozin”. Examples include empagliflozin, dapagliflozin, and canagliflozin. These treatments are recommended for the management of kidney disease in most patients.

You should not be taking study pills in addition to other medications of the same class (for example, do not take both study-provided empagliflozin and dapagliflozin together).

Empagliflozin is safe to take with other medication. BI 690517 clearance from the body can be affected by some other medications. These medications can still be taken together, but caution is recommended. We will send a letter about the study tablets to primary care doctors. The list of medications that might increase body levels of BI 690517 include:
probenecid, valproic acid (valproate), fluconazole, amitriptyline, clomipramine. Those medications that could reduce BI 690517 levels are rifampicin and phenytoin. Methotrexate should also be used with caution. Your study team will update you if there is any new information about interactions of study treatments with other medications.

If your local doctor thinks you should definitely start treatments which work in a similar way to either of the study treatments BI 690517 or empagliflozin) such as finerenone, you should stop your study pills first and inform your study team. You or they may call Freephone 0808 164 4060 with any queries.